Tianjin Lisheng Pharmaceutical Co (002393) Fair Value & Analysis
Healthcare · CN · Market cap 4.5B CNY
Fair value as of: Jun 25, 2026
Analysis
Tianjin Lisheng Pharmaceutical Co (002393) currently trades at ¥14.13, while our model-based Fair Value estimate is ¥27.13 — implying the stock looks roughly 92.0% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive system applications. Its products also include Shoubishan capsules, Jiayindapamide tablets, Sanyu Zhengtong tablets, Xifuni cefdinir dispersible tablets, and Youhao Maren soft capsules. In addition, the company provides pharmaceutical manufacturing outsourcing services and technology research and development services. Further, it exports its products. The company was founded in 1951 and is headquartered in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Jinhao Pharmaceutical Co., Ltd.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Tianjin Lisheng Pharmaceutical Co (002393) undervalued?
What is the fair value of 002393?
What is the quality score of 002393?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.